8-K: Indivior Completes US Redomiciliation, Nasdaq Listing Continues

Indivior Pharmaceuticals, Inc. has successfully completed its redomiciliation from the United Kingdom to the United States, with its common stock continuing to trade on Nasdaq under the symbol INDV.

Summary

• Indivior Pharmaceuticals, Inc. (a Delaware corporation, 'IPI') has become the new ultimate parent company, completing the U.S. Domestication.
• Indivior PLC (a UK company) has been renamed Indivior Ltd. and is now a wholly-owned subsidiary of IPI.
• Each ordinary share in Indivior U.K. was cancelled, and shareholders received one share of IPI common stock for every ordinary share previously held.
• IPI's common stock will begin trading on Nasdaq under the symbol INDV on January 26, 2026, the same symbol used by Indivior U.K.
• The redomiciliation was approved by Indivior shareholders at an extraordinary general meeting on December 11, 2025, and became effective on January 23, 2026, after market close.
• The company expects to strengthen its U.S. capital markets presence, increase potential U.S. equity indexation, simplify corporate governance, reduce complexity, and enhance its position as a U.S.-based treatment innovator.
• IPI is now subject to U.S. SEC reporting requirements as a domestic issuer and applicable Nasdaq exchange rules.
• The Note Purchase Agreement was amended to reflect IPI as the new reporting entity for financial statements and other financial matters.
• Indemnification agreements were authorized for IPI's directors and executive officers, providing indemnification to the fullest extent permitted under Delaware law.
• IPI assumed existing equity incentive plans (LTIP, 2024 LTIP, DBP, 2014 Savings Plan, 2024 Savings Plan) and amended them to reflect the use of IPI common stock.
• A new Indivior U.S. 2026 Omnibus Equity Incentive Plan was adopted, reserving up to 17,500,000 shares for awards, plus forfeited shares from prior plans.
• A Non-Employee Director Compensation Policy was adopted, outlining annual cash retainers and restricted stock unit awards for non-employee directors, with equity awards capped at $1,000,000 annually per director.
• New Certificate of Incorporation and Bylaws were filed in Delaware, establishing the company's capital structure (700,000,000 common shares, 70,000,000 preferred shares) and corporate governance provisions, including anti-takeover measures.
• A Global Code of Conduct and a Code of Ethics for Senior Financial Officers were adopted, substantially similar to those of Indivior U.K.
• An Executive Compensation Clawback Policy was adopted to comply with U.S. Clawback Rule and U.S. Listing Rule requirements.

Sentiment

Score: 8

Explanation: The company successfully completed a significant corporate restructuring (redomiciliation to the U.S.) which is expected to yield multiple strategic and financial benefits, including enhanced capital market presence, simplified governance, and improved market positioning. The transition involved comprehensive updates to legal, financial, and compensation frameworks, all executed as planned.

Positives

• Strengthened U.S. capital markets presence.
• Increased potential for U.S. equity indexation.
• Simplified corporate governance and reduced complexity.
• Enhanced positioning as a U.S.-based treatment innovator, fostering closer collaboration with public health leaders on SUBLOCADE for opioid use disorder.
• Continuity of trading symbol (INDV) on Nasdaq.
• New 2026 Omnibus Equity Incentive Plan with 17,500,000 shares reserved for awards, plus forfeited shares from prior plans, providing flexibility for employee incentives.

Risks

• Potential for penalties for trading on or communicating material nonpublic information, including jail terms, criminal fines, civil penalties, and civil enforcement injunctions.
• Liability for tippers for transactions by tippees.
• Control persons (Company and/or management/supervisory personnel) may be held liable for up to the greater of $1 million or three times the profit gained or loss avoided in insider trading violations.
• Risks related to the business, including voluntary withdrawal or regulatory order for product withdrawal, injunctions against manufacturing/marketing/selling products, revocation/suspension/rejection/limitation of Regulatory Required Permits, commencement of enforcement actions by FDA/DEA/US DHHS, invalidation/revocation/lapse of IP Rights, adverse test results for products, failure to comply with Corporate Integrity Agreements, entering into guilty pleas for felonies/corporate crimes, or removal from Material Third Party Payor Programs, any of which could result in a Material Adverse Effect.
• Uncertainty with respect to the proper application of Section 409A of the Code for deferred compensation, which could result in additional taxes or penalties for participants.

Future Outlook

The company anticipates strengthening its U.S. capital markets presence, increasing potential U.S. equity indexation, simplifying corporate governance, reducing complexity, and further positioning itself as a U.S.-based treatment innovator, enabling closer collaboration with public health leaders on advancing SUBLOCADE for opioid use disorder.

Management Comments

• Indivior believes the change in domicile will expand the benefits of its U.S. stock listing, including: Strengthening Indivior's U.S. capital markets presence, Increasing potential U.S. equity indexation, Simplifying corporate governance and reducing complexity, Further positioning Indivior as a U.S. based treatment innovator, enabling closer collaboration with public health leaders on advancing SUBLOCADE for opioid use disorder.

Industry Context

Indivior is a leader in long-acting injectable treatments for opioid use disorder (OUD), focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. The redomiciliation is expected to enhance its strategic positioning within the U.S. market, which is crucial for its core business.

Management Changes

Corporate Governance

Legal Proceedings

• The Note Purchase Agreement references 'non-recurring litigation or claim settlement Charges' as an add-back to Consolidated Adjusted EBITDA.
• Specific litigation settlement payments owed to the U.S. Department of Justice are outlined: $50,000,000 in January 2025, $50,000,000 in January 2026, $50,000,000 in January 2027, and $100,000,000 in December 2027.
• Risks include potential Material Adverse Effect from adverse proceedings, regulatory enforcement actions, or failure to comply with Corporate Integrity Agreements.

Related Party Transactions

• The filing mentions 'Tax Sharing Agreements with Affiliates' and 'intercompany indebtedness among Holdings and its Restricted Subsidiaries' as part of financial definitions and covenants, indicating ongoing related party dealings within the new corporate structure.
• Equity plans allow for awards to employees, directors, and consultants, who are considered related parties.

Stakeholder Impact

• Shareholders: Direct exchange of Indivior U.K. shares for IPI common stock, continued Nasdaq listing, potential for increased U.S. equity indexation, and simplified corporate governance.
• Employees/Management: Continuity of employment under the new U.S. parent, assumption and amendment of existing equity incentive plans, adoption of a new omnibus equity plan, and a defined non-employee director compensation policy.
• Customers/Public Health Leaders: Enhanced positioning as a U.S.-based treatment innovator, enabling closer collaboration on advancing SUBLOCADE for opioid use disorder.
• Creditors: Amendments to the Note Purchase Agreement to reflect the new reporting entity (IPI) and reaffirmation of security interests and guarantees by Note Parties.

Next Steps

• Indivior Pharmaceuticals, Inc. common stock will begin trading on Nasdaq under the symbol INDV at the start of trading on January 26, 2026.
• The company will continue to be subject to U.S. SEC reporting requirements as a domestic issuer and applicable Nasdaq exchange rules.
• Ongoing administration of the amended and new equity incentive plans.
• Continued focus on advancing SUBLOCADE for opioid use disorder.

Key Dates

Keywords

Indivior, redomiciliation, US domestication, Nasdaq, SEC filing, corporate governance, equity incentive plan, executive compensation, clawback policy, SUBLOCADE, opioid use disorder, financial reporting, risk management